


PHARMACEUTICAL 2020

Cellectar Biosciences Inc. Rank 316 of 362







Cellectar Biosciences Inc. Rank 316 of 362

The relative strengths and weaknesses of Cellectar Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Cellectar Biosciences Inc. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 60% points. The greatest weakness of Cellectar Biosciences Inc. is the variable Net Income, reducing the Economic Capital Ratio by 361% points.

The company's Economic Capital Ratio, given in the ranking table, is -612%, being 309% points below the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	11,386
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,770
Liabilities, Non-Current	422
Other Assets	430
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	86
Property and Equipment	435
Research and Development	8,996
Revenues	0
Selling, General and Administrative Expense	5,183

Output Variable	Value in 1000 USD
Assets	12,251
Liabilities	3,191
Expenses	14,179
Stockholders Equity	9,059
Net Income	-14,093
Comprehensive Net Income	-14,093
Economic Capital Ratio	-612%

